Microvast Holdings announces departure of chief financial officer
On Wednesday, Morgan Stanley (NYSE:MS) analysts downgraded Halozyme Therapeutics (NASDAQ:HALO) stock from Overweight to Equalweight and reduced the price target to $62.00 from $73.00, contributing to the stock’s significant 28% decline over the past week. According to InvestingPro data, the stock appears undervalued despite maintaining an EXCELLENT financial health rating and a perfect Piotroski Score of 9. The decision comes amidst concerns over draft guidance that could impact industry incentives and pose challenges for hyaluronidase combination products.
The draft guidance in question is expected to be finalized later this year, with its initial price applicability projected for 2028. During this period, there is an anticipation of increased discussions regarding bioavailability and its clinical significance. The Centers for Medicare & Medicaid Services (CMS) has highlighted scenarios where an active ingredient does not lead to a clinically meaningful difference, which is central to the ongoing debate.
Halozyme’s management has responded to these concerns by pointing out the clinical benefits of their ENHANZE technology, which improves drug bioavailability. They have referenced three recent instances where this technology has shown positive results. These include a threefold decrease in infusion-related reactions with Darzalex subcutaneous administration, a fivefold reduction with amivantamab subQ, and an exploratory analysis indicating that amivantamab subQ was superior in overall survival.
While Morgan Stanley acknowledges the validity of Halozyme’s stance, they also foresee the conversation about the clinical outcomes associated with improved bioavailability continuing until CMS concludes its review and finalizes the guidance. This ongoing uncertainty has influenced the firm’s decision to adjust their outlook on Halozyme Therapeutics’ stock. Despite the current market sentiment, the company maintains strong financials with a healthy current ratio of 8.4x and robust cash flows that adequately cover interest payments. Access detailed valuation models and the full Pro Research Report on InvestingPro to make more informed investment decisions.
In other recent news, Halozyme Therapeutics reported a strong first-quarter performance, with revenues reaching $264.9 million, a 35% increase from the previous year, and non-GAAP earnings per share rising to $1.11. This exceeded Benchmark’s expectations, which anticipated revenues of $240 million and EPS of $0.99. Despite these results, Leerink Partners downgraded Halozyme from Market Perform to Underperform, citing concerns over new draft guidance from the Centers for Medicare & Medicaid Services (CMS) that could affect drug pricing protections. The CMS guidance suggests that combination products, such as those involving Halozyme’s hyaluronidase, may face price negotiations sooner than expected. Evercore ISI, however, maintained its Outperform rating for Halozyme, highlighting ongoing discussions around the CMS draft guidance. Meanwhile, TD Cowen raised its price target for Halozyme to $79, up from $77, following the company’s robust quarterly results and revised fiscal year guidance. The firm noted strong royalty income from drugs like Darzalex and Phesgo as key contributors to Halozyme’s financial success. Halozyme also announced a new share repurchase program, signaling confidence in its financial health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.